Gaithersburg, Maryland – October 15, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO Investor Forum in San Francisco, California. CEO & President Doug Doerfler will present 22 October at 11:15 a.m.
Released : October 08, 2019 07:00 RNS Number : 0594P MaxCyte, Inc. 08 October 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting and Declaration of Audit Remuneration Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR), the global
Released : October 07, 2019 07:00 RNS Number : 9473O MaxCyte, Inc. 07 October 2019 Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines CAMBRIDGE, Mass. , and GAITHERSBURG, Md. , October 7, 2019 - Editas Medicine, Inc.
Gaithersburg, Maryland – October 2, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today its planned participation at key upcoming industry conferences. These conferences and events will provide an opportunity for MaxCyte to showcase how the Company is driving
Released : September 18, 2019 07:00 RNS Number : 6880M MaxCyte, Inc. 18 September 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2019 ¾ Strong commercial execution and financial performance with 21% year-over-year revenue growth ¾ Cell
Released : September 09, 2019 07:00 RNS Number : 5829L MaxCyte, Inc. 09 September 2019 MaxCyte Announces Presentation at ICLE 2019 Gaithersburg, Maryland - 9 September 2019 - MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company , announces today that
Released : August 14, 2019 07:00 RNS Number : 9483I MaxCyte, Inc. 14 August 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Gaithersburg, Maryland - 14 August 2019: MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life
Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell therapy platform for targeted cell-based immune therapies Gaithersburg, Maryland – July 23, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced
Released : July 17, 2019 07:00 RNS Number : 7557F MaxCyte, Inc. 17 July 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Significant CARMA™ programme progress, 80+ partnered programmes licensed and strong financial performance with 21% year over year revenue growth